Not really sure why MLNM don't just buy them...
NEW HAVEN, Conn., Jan. 7 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC - News) today announced that it has licensed its HAP(TM) Technology to Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) for use in its drug discovery and development programs. Under the terms of the non-exclusive, multi-year agreement, Millennium will pay Genaissance license fees. Genaissance will have certain rights to support Millennium's DNA biomarker and pharmacogenomic efforts.
"We are pleased to enter into this agreement with Millennium, as they have a track record of using leading edge technology for new product development," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "We look forward to developing a strong relationship with our colleagues at Millennium."
"As a leading biopharmaceutical company, Millennium is committed to personalized medicine, and we believe Genaissance's technology will allow us to accelerate our work in integrating DNA markers into clinical development and pharmaceutical products," said Geoff Ginsburg, M.D., Ph.D., Vice President of Molecular Medicine, Millennium Pharmaceuticals. |
